Abstract
PIMS (paediatric inflammatory multisystem syndrome associated with COVID-19 or Multisystem Inflammatory Syndrome in Children (MIS-C)) is a new disease classification, occurring in children and young adults associated with the SARS-CoV-2 infection. Although children suffer from COVID-19 infection asymptomatically or mildly, long-term complications of the disease may be more severe for them than for adults. Despite the fact that PIMS is a relatively new disease, we already know that it should not be underestimated. In spite of the clinical picture of these complications may resemble Kawasaki Disease (KD), we may notice some differences in laboratory tests (such as reduced number of lymphocytes, decreased platelet count or elevated ferritin levels). Although usually the first symptom of PIMS is high fever, it is followed by symptoms related to the digestive system, present in about 80% of cases. The insidious and severe gastrointestinal symptoms of PIMS can mimic abdominal surgical emergencies, including acute appendicitis, gastrointestinal infections or inflammatory bowel disease. Cardiovascular symptoms occur in approximately 60% of patients with PIMS. Immunomodulatory therapy plays an essential role in the treatment of PIMS. The exact causes of PIMS are recently unknown, however, it is explained as genetic hyperactivation of immunity. In this minireview we summarize the most recent data about this condition, mainly we are focusing on gastrointestinal and cardiovascular symptoms, short/long-term complications and treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.